ADMA Biologics Inc

Robbins Geller Rudman & Dowd LLP announced that investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 have until Monday, August 10, 2026 to seek lead plaintiff appointment in a class action lawsuit alleging securities fraud. The lawsuit claims ADMA Biologics and certain executives made false statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. A Culper Research report on March 24, 2026 alleged that ADMA Biologics' reported growth was driven by channel stuffing and an undisclosed related party distributor, causing the stock to drop over 16%. The following day, ADMA Biologics called the report misleading, but Cantor Fitzgerald downgraded the stock to Neutral from Overweight, leading to a further decline of more than 13%.

Berger Montague PC has filed a class action lawsuit against ADMA Biologics and reminds investors who purchased ADMA common stock between August 9, 2024 and March 25, 2026 that they have until August 10, 2026 to seek lead plaintiff appointment. The suit alleges ADMA engaged in a channel-stuffing scheme to inflate revenue growth amid declining demand for its flagship product ASCENIV and failed to disclose related party transactions. A March 24, 2026 Culper Research report claimed that without the alleged scheme, ADMA would have seen a 3 percent revenue decline in 2025 instead of the reported 20 percent growth. Following the report, ADMA shares fell 16 percent on March 24 and an additional 15 percent on March 25, closing at $9.63 per share.

Kahn Swick & Foti, LLC has notified investors in ADMA Biologics, Inc. of an August 10, 2026 deadline to apply for lead plaintiff in a securities class action lawsuit. The lawsuit, pending in the United States District Court for the District of New Jersey, seeks to recover losses for investors who purchased ADMA securities between August 9, 2024 and March 25, 2026. The complaint alleges that the company and certain executives failed to disclose material information, including an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. Investors who suffered losses during the class period may contact KSF Managing Partner Lewis Kahn to learn more about the case, which is captioned Mazzarino v. ADMA Biologics, Inc., et al, No. 26-cv-04793.

Pomerantz LLP has filed a class action lawsuit against ADMA Biologics, Inc. over potential securities fraud or unlawful business practices. Investors who purchased or acquired ADMA securities during the Class Period have until August 10, 2026 to seek appointment as Lead Plaintiff. The lawsuit follows a March 24, 2026 short report from Culper Research alleging that ADMA's reported growth was driven by channel stuffing and an undisclosed related party distributor, causing the stock to fall $2.26 per share, or 16.63%, to close at $11.33. Two days later, Cantor Fitzgerald downgraded ADMA, citing an inadequate response to the Culper report, and the stock fell an additional $1.34 per share, or 13.91%, to close at $8.29.

Rosen Law Firm reminds purchasers of ADMA Biologics securities between August 9, 2024 and March 25, 2026 of the August 10, 2026 lead plaintiff deadline in a securities class action first filed by the firm. Investors with losses exceeding $100,000 are encouraged to secure counsel before the deadline. The lawsuit alleges that ADMA Biologics made materially false and misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. When the true details entered the market, investors allegedly suffered damages. The firm notes that it achieved the largest ever securities class action settlement against a Chinese company and has recovered billions of dollars for investors.

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against ADMA Biologics, Inc. and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired ADMA securities between August 9, 2024 and March 25, 2026. The complaint claims the company made false or misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. Investors have until August 10, 2026 to seek lead plaintiff appointment. The law firm is handling the case on a contingency fee basis.

Holzer & Holzer, LLC reminds investors of upcoming deadlines to seek lead plaintiff appointment in shareholder class action lawsuits against BitGo Holdings, ADMA Biologics, and Via Transportation. The BitGo suit alleges defendants made false or misleading statements about risks from falling digital asset prices, with a lead plaintiff deadline of August 7, 2026. The ADMA Biologics case covers purchases between August 9, 2024 and March 25, 2026, alleging channel stuffing to inflate revenue, and has a deadline of August 10, 2026. The Via Transportation lawsuit concerns alleged misstatements in IPO offering documents about revenue growth and expansion, with a deadline of August 10, 2026. Investors who suffered losses are encouraged to contact the firm to discuss their legal rights.

Lowey Dannenberg P.C. is investigating ADMA Biologics for potential violations of federal securities laws. The investigation follows a March 24, 2026 report by Culper Research alleging that ADMA Biologics engaged in channel stuffing by inducing a distributor to stock excess ASCENIV through rebates and extended payment terms, which allowed the company to report 20% revenue growth in 2025 instead of an actual 3% decline. Attorney Andrea Farah stated the probe concerns whether the company and its executives provided accurate and complete information to investors. Investors who suffered losses exceeding $50,000 in ADMA Biologics securities are encouraged to contact the firm.

Hagens Berman has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. and set a lead plaintiff deadline of August 10, 2026 for investors who suffered substantial losses. The lawsuit covers a class period from August 9, 2024 through March 25, 2026 and alleges that the company artificially inflated its stock price by misrepresenting its financial condition, revenue recognition, and business practices. Specifically, the complaint claims ADMA engaged in an undisclosed related party transaction, used channel stuffing to create the appearance of revenue, and lacked adequate internal controls. The alleged misconduct was revealed through a series of corrective events, including a Culper Research short-seller report on March 24, 2026 that triggered a combined two-day stock decline of 31.6 percent, followed by a further 13.9 percent drop on March 26 after the company responded and Cantor Fitzgerald downgraded the stock. Investors with significant losses are encouraged to contact the firm before the August 10 deadline to seek lead plaintiff status.

Bernstein Liebhard LLP reminds ADMA Biologics, Inc. investors that the deadline to join a securities fraud class action lawsuit is August 10, 2026. The lawsuit, filed on behalf of investors who purchased or acquired ADMA securities between August 9, 2024 and March 25, 2026, alleges that the company and certain senior officers made materially false and misleading statements about its business operations, growth prospects, and financial stability, causing shares to trade at artificially inflated prices. Investors who suffered losses are encouraged to submit a form or contact Investor Relations Manager Peter Allocco at (212) 951-2030. Those wishing to serve as lead plaintiff must file papers by the deadline, though participation in any recovery does not require serving as lead plaintiff.

Pomerantz LLP reminds investors in ADMA Biologics, Inc. that a class action lawsuit has been filed against the company and certain officers and directors over possible securities fraud. The deadline to seek appointment as lead plaintiff is August 10, 2026, for those who purchased or acquired ADMA securities during the class period. The suit follows a March 24, 2026, short report by Culper Research alleging ADMA's growth was driven by channel stuffing and an undisclosed related party distributor, causing the stock to fall $2.26 per share, or 16.63%, to $11.33. Two days later, Cantor Fitzgerald downgraded ADMA, citing a disappointing response to the report, and the stock fell another $1.34 per share, or 13.91%, to $8.29.

Rosen Law Firm reminds purchasers of ADMA Biologics securities between August 9, 2024 and March 25, 2026 of the August 10, 2026 lead plaintiff deadline in a securities class action first filed by the firm. The lawsuit alleges that ADMA Biologics made materially false and misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. Investors who purchased ADMA Biologics securities during the class period may be entitled to compensation through a contingency fee arrangement. Rosen Law Firm highlights its track record, including the largest securities class action settlement against a Chinese company and over $438 million recovered for investors in 2019.

The Gross Law Firm has issued a shareholder alert for a securities class action lawsuit against ADMA Biologics, Inc. The class period runs from August 9, 2024 to March 25, 2026, with a lead plaintiff deadline of August 10, 2026. The complaint alleges that the company made false and misleading statements and failed to disclose an undisclosed related party transaction, the use of channel stuffing to inflate revenue, and a lack of adequate internal controls. Shareholders who purchased ADMA shares during the class period and suffered losses are encouraged to register for the case.

A class action lawsuit has been filed against ADMA Biologics and certain senior executives for securities fraud. The suit alleges that the company's reported 20% growth for 2025 was driven by a channel stuffing scheme, and that it failed to disclose related party transactions. On March 24, 2026, Culper Research published a report claiming ADMA induced a distributor to stock excess ASCENIV through rebates and extended payment terms, and that without this scheme revenue would have declined 3% instead of growing 20%. The news caused ADMA's stock to drop 16.6% on March 24, 2026, and a further 15% the following day. Investors have until August 10, 2026, to seek lead plaintiff appointment in the case pending in the U.S. District Court for the District of New Jersey.

The Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics, with lead plaintiff deadlines approaching in August 2026. For BitGo Holdings, the complaint alleges that defendants understated the risk of declining digital asset prices on the company's business and financial performance, with a lead plaintiff deadline of August 7, 2026. Via Transportation faces allegations that its annual recurring revenue per customer was declining and regulatory issues in Germany would hinder its expansion strategy, with a deadline of August 10, 2026. The Zillow Group suit claims the company mischaracterized its acquisition of Redfin as a partnership, exposing it to heightened antitrust scrutiny, also with an August 10 deadline. ADMA Biologics is accused of engaging in an undisclosed related party transaction and channel stuffing to inflate revenue, with the same August 10 deadline.

Holzer and Holzer LLC reminds investors of upcoming deadlines to seek lead plaintiff appointment in shareholder class action lawsuits against PicS N.V., BitGo Holdings, Inc., and ADMA Biologics, Inc. The PicS suit alleges misstatements in IPO offering documents regarding credit evaluation procedures, with a lead plaintiff deadline of August 4, 2026. The BitGo case claims the company failed to disclose risks from falling digital asset prices, and investors have until August 7, 2026 to move for lead plaintiff. The ADMA Biologics action, covering purchases between August 9, 2024 and March 25, 2026, alleges channel stuffing to inflate revenue, with a lead plaintiff deadline of August 10, 2026.

The Gross Law Firm has issued a notice to ADMA Biologics shareholders regarding a securities class action, with a lead plaintiff deadline of August 10, 2026. The class period runs from August 9, 2024 to March 25, 2026. The complaint alleges that ADMA Biologics made false or misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. Shareholders who purchased ADMA shares during the class period are encouraged to contact the firm, though participation in any recovery does not require lead plaintiff appointment.

Rosen Law Firm reminds purchasers of ADMA Biologics securities between August 9, 2024 and March 25, 2026 of the August 10, 2026 lead plaintiff deadline in a securities class action first filed by the firm. If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The lawsuit alleges that ADMA Biologics made false and misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. Investors with losses in excess of $100,000 are encouraged to secure counsel before the deadline.

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ADMA Biologics and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired ADMA securities between August 9, 2024 and March 25, 2026. The complaint claims the company made false or misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. Investors have until August 10, 2026 to seek lead plaintiff appointment. The law firm is handling the case on a contingency fee basis.

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of Via Transportation, Zillow Group, ADMA Biologics, and Erasca, with a lead plaintiff deadline of August 10, 2026. The Via Transportation suit covers a class period from September 9, 2025 to June 9, 2026 and alleges the company failed to disclose declining ARR per customer and regulatory issues hindering its German expansion. The Zillow Group suit, covering February 11, 2025 to May 7, 2026, claims the company mischaracterized its Redfin deal as a partnership rather than an acquisition, exposing it to heightened antitrust risk. ADMA Biologics is accused of undisclosed related party transactions, channel stuffing, and inadequate internal controls during the period from August 9, 2024 to March 25, 2026. The Erasca suit, covering January 14, 2025 to April 26, 2026, alleges that preclinical data for ERAS-0015 relied on improper comparisons and risked patent and trade secret violations.

Grabar Law Office is investigating potential fiduciary duty breaches by officers and directors of ADMA Biologics, Commvault Systems, Erasca, and Hub Group. For ADMA Biologics, the probe concerns allegations of inadequate internal controls, channel-stuffing, and undisclosed related-party transactions, with a March 2026 research report claiming revenue growth was overstated. The Commvault investigation focuses on allegedly misleading statements about annual recurring revenue growth guidance for fiscal year 2026. Erasca is under scrutiny for allegedly making improper comparisons between its drug candidate ERAS-0015 and Revolution Medicines' RMC-6236, and for failing to disclose related intellectual property risks, with the stock declining after April 2026 disclosures of a patient death and patent infringement allegations. Hub Group is alleged to have issued financial statements from Q1 2023 to Q3 2025 containing material misstatements due to premature revenue recognition and understated transportation costs. Long-term shareholders who purchased before specified dates and still hold shares may seek corporate reforms and damages at no cost.

The Law Offices of Howard G. Smith reminds investors of upcoming lead plaintiff deadlines in securities fraud class actions against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. For BitGo, the deadline is August 7, 2026, with allegations that the company understated risks from declining digital asset prices. Via Transportation faces an August 10 deadline over claims it misrepresented declining average revenue per customer and regulatory issues in Germany. Zillow Group's August 10 deadline involves allegations that its Redfin agreement was an undisclosed acquisition, heightening antitrust risk. ADMA Biologics also has an August 10 deadline, with claims of an undisclosed related party transaction and channel stuffing to inflate revenue.

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ADMA Biologics and certain officers, alleging securities law violations. The suit covers investors who purchased ADMA securities between August 9, 2024 and March 25, 2026. The complaint claims the company engaged in an undisclosed related party transaction, used channel stuffing to inflate revenue, and lacked adequate internal controls, rendering its statements materially false and misleading. Investors have until August 10, 2026 to seek lead plaintiff appointment. The firm represents investors on a contingency fee basis.

Faruqi & Faruqi, LLP reminds investors of the August 10, 2026 deadline to seek lead plaintiff in a securities class action against ADMA Biologics. The lawsuit alleges the company made false statements and failed to disclose a related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. A March 24, 2026 Culper Research report claimed ADMA induced a distributor to stock excess ASCENIV, causing the stock to drop 29% over two trading days. Investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 may be eligible to participate.

משרד רוזן עורכי דין מזכיר לרוכשי ניירות הערך של ADMA Biologics בין 9 באוגוסט 2024 ל-25 במרץ 2026 כי המועד האחרון להגשת תביעה ייצוגית בניירות ערך הוא 10 באוגוסט 2026. על פי התביעה, החברה מסרה הצהרות כוזבות ומטעות לגבי עסקת צד קשורה שלא פורסמה, שימוש בהצבת ערוצים ליצירת מראית עין של הכנסות, והיעדר בקרה פנימית נאותה. משרד רוזן, המתמחה בתביעות ייצוגיות בניירות ערך, השיג בעבר את הסדר התביעה הייצוגית הגדול ביותר נגד חברה סינית והחזיר מאות מיליוני דולרים למשקיעים. משקיעים המעוניינים להצטרף לתביעה או לשמש כתובע מרכזי יכולים לפנות למשרד עד למועד האחרון.

Rosen Law Firm reminds purchasers of ADMA Biologics securities between August 9, 2024 and March 25, 2026 of the August 10, 2026 lead plaintiff deadline in a securities class action first filed by the firm. The lawsuit alleges that ADMA Biologics made materially false and misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to create an appearance of revenue, and inadequate internal controls. Investors who purchased ADMA Biologics securities during the class period may be entitled to compensation through a contingency fee arrangement. To serve as lead plaintiff, investors must move the Court no later than August 10, 2026.

Glancy Prongay Wolke & Rotter LLP reminds investors that the deadline to file a lead plaintiff motion in the class action against ADMA Biologics, Inc. is August 10, 2026. The lawsuit covers investors who purchased ADMA securities between August 9, 2024 and March 25, 2026. The complaint alleges the company made false and misleading statements and failed to disclose that it engaged in an undisclosed related party transaction and used channel stuffing to inflate revenue. On March 24, 2026, Culper Research published a report claiming ADMA induced a distributor to stock excess ASCENIV by offering rebates and extended payment terms, causing the stock to fall 29.1% over two days to close at $9.63 per share on March 25, 2026.

A class action lawsuit has been filed against ADMA Biologics and certain senior executives for securities fraud. The suit alleges that the company's reported 20% growth for 2025 was driven by a channel stuffing scheme, and that it failed to disclose related party transactions. On March 24, 2026, Culper Research published a report claiming ADMA induced a distributor to stock excess ASCENIV through rebates and extended payment terms, and that without this scheme, revenue would have declined 3% in 2025. The stock fell 16.6% that day, and continued to drop over subsequent days following an analyst downgrade. Investors have until August 10, 2026, to seek lead plaintiff appointment in the case pending in the U.S. District Court for the District of New Jersey.

A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. on behalf of investors who purchased or acquired ADMA securities between August 9, 2024 and March 25, 2026. The lawsuit, filed in the United States District Court for the District of New Jersey, alleges that the company made materially false and misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. The complaint follows a March 24, 2026 report by Culper Research that accused ADMA of channel stuffing and an undisclosed related party distributor, causing the stock to fall 29.1% over two days to close at $9.63 per share on March 25, 2026. Investors have until August 10, 2026 to seek appointment as lead plaintiff through counsel such as Kessler Topaz Meltzer & Check, LLP.

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of Via Transportation, Zillow Group, and ADMA Biologics, with a lead plaintiff deadline of August 10, 2026. The Via Transportation class action covers a class period from September 9, 2025 to June 9, 2026, alleging that the company failed to disclose declining ARR per customer and regulatory issues hindering its German expansion. The Zillow Group class action covers a class period from February 11, 2025 to May 7, 2026, alleging that the company mischaracterized its acquisition of Redfin as a partnership, leading to heightened antitrust risk. The ADMA Biologics class action covers a class period from August 9, 2024 to March 25, 2026, alleging undisclosed related party transactions, channel stuffing, and inadequate internal controls.

Holzer & Holzer reminds investors of upcoming lead plaintiff deadlines in shareholder class action lawsuits against BitGo Holdings, ADMA Biologics, and Erasca. The deadline for the BitGo case, which alleges misleading statements about risks from falling digital asset prices, is August 7, 2026. Deadlines for the ADMA Biologics case, covering a class period from August 9, 2024 to March 25, 2026 regarding business and financial practices, and the Erasca case, concerning ERAS-0015 between January 14, 2025 and April 26, 2026, are both August 10, 2026. Investors who purchased shares and suffered losses are encouraged to contact the firm to discuss their legal rights.

Kirby McInerney LLP reminds investors that a securities fraud class action lawsuit has been filed on behalf of purchasers of ADMA Biologics securities between August 9, 2024 and March 25, 2026. The lawsuit alleges that ADMA engaged in an undisclosed related party transaction, used channel stuffing to create an appearance of revenue, and lacked adequate internal controls. Following a March 24, 2026 short seller report by Culper Research alleging channel stuffing and an undisclosed related party distributor, ADMA shares fell 17% on March 24 and an additional 15% on March 25. A subsequent downgrade by Cantor Fitzgerald on March 26, citing lack of clarity and cash flow inconsistencies, led to a further 14% decline. Investors have until August 10, 2026 to request lead plaintiff appointment.

ADMA Biologics is facing a federal securities lawsuit alleging it inflated revenues of its flagship product through channel stuffing and concealed a distribution relationship tied to an entity allegedly controlled by a senior executive. The complaint, filed in the U.S. District Court for the District of New Jersey, claims the company and certain senior executives made materially false and misleading statements about revenue growth, internal controls, and related-party transactions. The allegations follow a Culper Research short-seller report published on March 24, 2026, after which ADMA shares fell roughly 16.6% that day, another 15% on March 25, and an additional 13.9% on March 26, closing at $8.29, down from about $13.59 before the report. Cantor Fitzgerald noted the company's response lacked specific feedback addressing the report's claims. The lawsuit was reported on June 15, 2026, just days after Raymond James resumed coverage with an Outperform rating and a $21 price target, citing ADMA's transformation into a profitable, high-growth company insulated from certain policy risks.